Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1151-1159

  Zhu, Yongqiang ^a,b   Zheng, Yi ^a,b   Mei, Lin ^a,b   Liu, Mengqiong ^c   Li, Shanshan ^d   Xiao, Huawei ^a,b   Zhu, Huijun ^a,b   Wu, Shu ^a,b   Chen, Hongbo ^a,b   Huang, Laiqiang ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b Center for Biotech and BioMedicine   (China)

^c HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^d IOWA STATE UNIVERSITY   (United States)

Author keywords

Cervical cancer; Dendritic cell; Human papillomavirus; Suppressors of cytokine signaling 1; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; PROTEIN E7; SHORT HAIRPIN RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CANCER MODEL; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE SILENCING; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS MUTANT; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; PAPILLOMAVIRUS E7 PROTEINS; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84882395190     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2027     Document Type: Article

References (39)

1. Jemal A, Bray F and Center MM: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Berzofsky JA, Terabe M, Oh SK, Belyakov IM, Ahlers JD, Janik JE and Morris JC: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113: 1515-1525, 2004.
3. Ali M and Monk BJ: Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10: 528-538, 2005.
4. Kanodia S, Da Silva DM and Kast WM: Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122: 247-259, 2008.
5. Psyrri A and Daniel D: Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol 5: 24-31, 2008.
6. Brinton LA: Epidemiology of cervical cancer: overview. IARC Sci Publ 119: 3-23, 1992.
7. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
8. Kobayashi T and Yoshimura A: Keeping DCs awake by putting SOCS1 to sleep. Trends Immunol 26: 177-179, 2005.
9. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D and Pecorelli S: Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol 73: 5402-5410, 1999.
10. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM and Hung CF: Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65: 309-316, 2005.
11. Kelvin EK, Song XT, Aldrich M, Huang XF and Chen SY: SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116: 90-100, 2006.
12. Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, Huang XF and Chen SY: An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3: 76-93, 2006.
13. Akita H, Kogure K, Moriguchi R, Nakamura Y and Higashi T: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J Control Release 143: 311-317, 2010.
14. Kubo M, Hanada T and Yoshimura A: Suppressors of cytokine signaling and immunity. Nat Immunol 4: 1169-1176, 2003.
15. Alexander WS and Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503-529, 2004.
16. Shen L, Evel-Kabler K, Strube R and Chen SY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22: 1546-1553, 2004.
17. Hong B, Ren W, Song XT and Evel-Kabler K: Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res 69: 8076-8084, 2009.
18. Hanada T, Yoshida H, Kato S, Tanaka K and Masutani K: Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19: 437-450, 2003.
19. Guenterberg KD, Lesinski GB, Mundy-Bosse BL and Karpa VI: Enhanced anti-tumor activity of interferon-alpha in SOCS1-defi cient mice is mediated by CD4+ and CD8+ T cells. Cancer Immunol Immunother 60: 1281-1288, 2011.
20. Carow B, Ye Xq, Gavier-Widén D, Bhuju S and Oehlmann W: Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an IFN-dependent. J Biol Chem 286: 26873-26887, 2011.
21. Münger K, Basile JR, Duensing S, Eichten A and Gonzalez SL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898, 2001.
22. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK and Le Poole IC: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16E6 and E7 genes. Vaccine 22: 520-527, 2004.
23. Brinkman JA, Xu XM and Kast WM: The efficacy a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV 16 induced tumors. Vaccine 25: 3437-3444, 2007.
24. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM and Drijfhout JW: Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249, 1993.
25. Liu HG, Fan ZP, Chen WW, Yang HY, Liu QF and Zhang H: A mutant HBs antigen (HbsAg) 183-191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients. Clin Exp Immunol 151: 441-447, 2008.
26. Zheng Y, Zhang Y, Ma Y, Wan J and Shi C: Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. J Microbiol 46: 728-736, 2008.
27. Brinkman JA, Caffrey AS and Muderspach LI: The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol 26: 129-142, 2005.
28. Münger K, Phelps WC, Bubb V and Howley PM: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417-4421, 1989.
29. Phelps WC, Yee CL and Munger K: The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53: 539-547, 1988.
30. Nonn M, Schinz M, Zumbach K, Pawlita M and Schneider A: Dendritic cell-based tumor vaccine for cervical cancer I: in vitro vaccination with recombinant protein pulsed dendritic cells induces specific T cells to HPV16 E7 and HPV18 E7. J Cancer Res Clin Oncol 129: 511-520, 2003.
31. Santin AD, Bellone S, Gokden M and Cannon MJ: Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346: 1752-1753, 2002.
32. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A and Siegel ER: Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82: 1968-1979, 2008.
33. Ferrara A, Nonn M, Sehr P, Schreckenberger C and Pawlita M: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129: 521-530, 2003.
34. Hashimoto M, Ayada T, Kinjyo I, Hiwatashi K and Yoshida H: Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci 100: 730-736, 2009.
35. Judge AD, Sood V, Shaw JR, Fang D and McClintock K: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462, 2005.
36. Hornung V, Guenthner-Biller M, Bourquin C and Ablasser A: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270, 2005.
37. Sledz CA, Holko M, de Veer MJ and Silverman RH: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839, 2003.
38. Basak SK, Kiertscher SM and Harui A: Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol 17: 182-196, 2004.
39. Benihoud K, Yeh P and Perricaudet M: Adenovirusvectors for gene delivery. Biotechnology 10: 440-447, 1999.